On Tuesday, Medtronic PLC (MDT.US) rose 4% in pre-market trading to $100.14. The company reported Q2 FY2026 non-GAAP earnings per share (EPS) of $1.36, up from $1.26 a year earlier and surpassing the $1.31 consensus estimate from FactSet analysts.
Quarterly net sales reached $8.96 billion for the period ending October 24, compared to $8.4 billion in the prior-year quarter and exceeding the $8.87 billion analyst forecast.
For FY2026, Medtronic now projects non-GAAP EPS between $5.62 and $5.66, narrowing its prior guidance of $5.60–$5.66. The FactSet consensus stood at $5.62. The updated outlook includes an estimated $185 million tariff impact.
Additionally, the company raised its FY2026 revenue growth forecast to 5.5%, up from the previous 5% projection.
Comments